Benefits of rivastigmine on attention in dementia associated with Parkinson disease

Neurology. 2005 Nov 22;65(10):1654-6. doi: 10.1212/01.wnl.0000184517.69816.e9.

Abstract

In a 24-week, randomized, double-blind, placebo-controlled, multicenter study of rivastigmine, 487 patients with dementia associated with Parkinson disease underwent assessment of attention on the Cognitive Drug Research computerized cognitive assessment system before dosing and 16 and 24 weeks later. Significant benefits of rivastigmine over placebo were seen on all aspects of attention assessed: sustained attention, focused attention, consistence of responding, and central processing speed.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Attention / drug effects*
  • Attention / physiology
  • Cognition / drug effects
  • Cognition / physiology
  • Cognition Disorders / drug therapy
  • Cognition Disorders / etiology
  • Cognition Disorders / psychology
  • Corpus Striatum / drug effects
  • Corpus Striatum / physiopathology
  • Dementia / drug therapy*
  • Dementia / etiology*
  • Dementia / psychology
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Frontal Lobe / drug effects
  • Frontal Lobe / physiopathology
  • Humans
  • Male
  • Middle Aged
  • Neural Pathways / drug effects
  • Neural Pathways / physiopathology
  • Neuroprotective Agents / administration & dosage*
  • Neuropsychological Tests
  • Parkinson Disease / complications*
  • Phenylcarbamates / administration & dosage*
  • Placebos
  • Reaction Time / drug effects
  • Reaction Time / physiology
  • Rivastigmine
  • Treatment Outcome

Substances

  • Neuroprotective Agents
  • Phenylcarbamates
  • Placebos
  • Rivastigmine